EGFR
Los inhibidores del receptor del factor de crecimiento epidérmico (EGFR) son compuestos que bloquean la señalización del EGFR, un receptor que a menudo está sobreexpresado en varios tipos de cáncer y que juega un papel crucial en la angiogénesis. Los inhibidores del EGFR se utilizan para prevenir el crecimiento tumoral y las metástasis al interrumpir las vías que promueven la formación de vasos sanguíneos en los tumores. Estos inhibidores son ampliamente utilizados en la investigación y terapia contra el cáncer. En CymitQuimica, ofrecemos una amplia selección de inhibidores de EGFR de alta calidad para apoyar su investigación en oncología y angiogénesis.
Se han encontrado 572 productos de "EGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tarlox-TKI
CAS:<p>Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.</p>Fórmula:C19H18BrClN6OPureza:97.03%Forma y color:SolidPeso molecular:461.74EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Fórmula:C31H37Cl2N7O3SForma y color:SolidPeso molecular:658.64EGFR-IN-67
CAS:<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Fórmula:C18H17N3SForma y color:SolidPeso molecular:307.41EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Fórmula:C17H14N4O4S3Forma y color:SolidPeso molecular:434.51EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Fórmula:C36H44BrN10O2PForma y color:SolidPeso molecular:759.68NSC81111
CAS:<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Fórmula:C19H16O4Forma y color:SolidPeso molecular:308.33EGFR-IN-73
CAS:<p>EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1].</p>Fórmula:C19H17ClFN3O4Pureza:98%Forma y color:SolidPeso molecular:405.81Antiproliferative agent-34
CAS:<p>Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT.</p>Fórmula:C27H27N7O5Pureza:98%Forma y color:SolidPeso molecular:529.55EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Fórmula:C26H31FN8O2SPureza:98%Forma y color:SolidPeso molecular:538.64AG-183
CAS:<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Fórmula:C13H8N4O3Forma y color:Brown SolidPeso molecular:268.23EGFR-IN-16
CAS:<p>EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.</p>Fórmula:C16H11NO3Pureza:98%Forma y color:SolidPeso molecular:265.26(E/Z)-AG490
CAS:<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Fórmula:C17H14N2O3Forma y color:SolidPeso molecular:294.3EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Fórmula:C10H6N6S2Forma y color:SolidPeso molecular:274.32CGP52411
CAS:<p>CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM).</p>Fórmula:C20H15N3O2Pureza:99.78%Forma y color:SolidPeso molecular:329.35EGFR-IN-50
CAS:<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Fórmula:C24H26BrN3O4S2Forma y color:SolidPeso molecular:564.51EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Fórmula:C14H13N3O2SForma y color:SolidPeso molecular:287.34EGFR-IN-28
CAS:<p>EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .</p>Fórmula:C31H39BrN10O3SForma y color:SolidPeso molecular:711.68NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C22H20O4Forma y color:SolidPeso molecular:348.39BAY 2476568
CAS:<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Fórmula:C24H27FN4O4Forma y color:SolidPeso molecular:454.49LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Fórmula:C32H35N5O3Forma y color:SolidPeso molecular:537.65Lavendustin C6
CAS:<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Fórmula:C20H25NO5Forma y color:SolidPeso molecular:359.42PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Fórmula:C28H26N8O4Forma y color:SolidPeso molecular:538.56Nazartinib mesylate
CAS:<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Fórmula:C27H35ClN6O5SPureza:98%Forma y color:SolidPeso molecular:591.12Tyrphostin AG 112
CAS:<p>Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.</p>Fórmula:C13H8N4OPureza:97.01%Forma y color:SolidPeso molecular:236.23DBPR112
CAS:<p>DBPR112: oral furanopyrimidine EGFR inhibitor; IC50: 15 nM (EGFRWT), 48 nM (L858R/T790M); blocks ATP site, strong antitumor effects.</p>Fórmula:C32H31N5O3Pureza:99.25%Forma y color:SolidPeso molecular:533.62Epertinib
CAS:<p>Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).</p>Fórmula:C30H27ClFN5O3Pureza:98%Forma y color:SolidPeso molecular:560.02MS 39
CAS:<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Fórmula:C55H71ClFN9O7SForma y color:SolidPeso molecular:1056.72RTC-5
CAS:<p>RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.</p>Fórmula:C24H22ClF3N2O3SPureza:98.14%Forma y color:SolidPeso molecular:510.96SDZ281-977
CAS:<p>SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.</p>Fórmula:C18H20O5Pureza:99.64%Forma y color:SolidPeso molecular:316.35EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Fórmula:C26H33N9O3SPureza:98.52% - 99.79%Forma y color:SolidPeso molecular:551.66Gefitinib N-oxide
CAS:<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Fórmula:C22H24ClFN4O4Pureza:98%Forma y color:SolidPeso molecular:462.9Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Pureza:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Forma y color:LiquidEGFR-IN-5
CAS:<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Fórmula:C31H38FN9OPureza:98.17%Forma y color:SolidPeso molecular:571.69BKI-1369
CAS:<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Fórmula:C23H27N7OForma y color:SolidPeso molecular:417.51EGFR-IN-68
CAS:<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Fórmula:C24H22N2OForma y color:SolidPeso molecular:354.44JBJ-04-125-02
CAS:<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Fórmula:C29H26FN5O3SPureza:98%Forma y color:SolidPeso molecular:543.61EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Fórmula:C27H27F3N6O2SForma y color:SolidPeso molecular:556.6Mutated EGFR-IN-2
CAS:<p>Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.</p>Fórmula:C29H35FN8O3Pureza:98%Forma y color:SolidPeso molecular:562.64GW 583340 dihydrochloride
CAS:<p>GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 inhibitor and inhibits 80% of tumor growth in a mouse xenograft mode.</p>Fórmula:C28H27Cl3FN5O3S2Pureza:98.80%Forma y color:SolidPeso molecular:671.03EGFR-IN-64
CAS:<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Fórmula:C20H21N3O3Forma y color:SolidPeso molecular:351.4JNJ28871063 hydrochloride
CAS:<p>ErbB receptor family inhibitor</p>Fórmula:C24H28Cl2N6O3Pureza:98%Forma y color:SolidPeso molecular:519.42Mutated EGFR-IN-3
CAS:<p>Mutated EGFR-IN-3: ATP-competitive, selective dibenzodiazepinone inhibitor for EGFR mutations, IC50 12-13 nM.</p>Fórmula:C31H29FN4O2Pureza:98%Forma y color:SolidPeso molecular:508.59EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Fórmula:C24H25ClN6O3Forma y color:SolidPeso molecular:480.95Selatinib
CAS:<p>Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.</p>Fórmula:C29H26ClFN4O3SPureza:98.00%Forma y color:SolidPeso molecular:565.06EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Fórmula:C25H25Cl2N7O2Forma y color:SolidPeso molecular:526.42EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Fórmula:C22H15N5O2SForma y color:SolidPeso molecular:413.45EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Fórmula:C32H36FN7O2Forma y color:SolidPeso molecular:569.67EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Fórmula:C26H23N5O3Forma y color:SolidPeso molecular:453.49Tyrphostin 51
CAS:<p>Tyrphostin 51 is an effective inhibitor of EGFR kinase.</p>Fórmula:C13H8N4O3Pureza:98%Forma y color:SolidPeso molecular:268.23EGFR-IN-25
CAS:<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Fórmula:C34H43N9O2Forma y color:SolidPeso molecular:609.76MS 154N
CAS:<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Fórmula:C47H56ClFN8O8Forma y color:SolidPeso molecular:915.45JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Fórmula:C31H30ClFN4O3SForma y color:SolidPeso molecular:593.11PD 173955-Analog1
CAS:<p>PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.</p>Fórmula:C21H14Cl2N4O3Forma y color:SolidPeso molecular:441.27EGA
CAS:<p>EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.</p>Fórmula:C16H16BrN3OPureza:98% - 99.6%Forma y color:SolidPeso molecular:346.22DS21360717
CAS:<p>DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.</p>Fórmula:C21H23N7OPureza:98%Forma y color:SolidPeso molecular:389.45EGFR/HER2-IN-2
CAS:<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Fórmula:C26H23N5O3Forma y color:SolidPeso molecular:453.49UNC-CA359
CAS:<p>UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.</p>Fórmula:C18H14ClN3O2Forma y color:SolidPeso molecular:339.78CAY10717
CAS:<p>CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.</p>Fórmula:C29H25F3N6O3Forma y color:SolidPeso molecular:562.54Cloperastine fendizoate
CAS:<p>Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).</p>Fórmula:C40H38ClNO5Pureza:99.97%Forma y color:SolidPeso molecular:648.19Falnidamol
CAS:<p>Falnidamol (BIBX 1382), an oral selective EGFR inhibitor, IC50 3 nM, weak on ErbB2 and others, anti-cancer pyrimido-pyrimidine.</p>Fórmula:C18H19ClFN7Pureza:98.816%Forma y color:SolidPeso molecular:387.84A-935142
CAS:<p>A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.</p>Fórmula:C18H19F3N2O2Pureza:98.97% - 99.91%Forma y color:SolidPeso molecular:352.35EMI1
CAS:<p>EMI1 targets mutated EGFR in drug-resistant NSCLC research.</p>Fórmula:C20H18N2O3Pureza:99.96%Forma y color:SolidPeso molecular:334.37EGFR-IN-9
CAS:<p>EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M).</p>Fórmula:C29H24N4O3Pureza:99.8%Forma y color:SolidPeso molecular:476.53Rezivertinib
CAS:<p>Rezivertinib (BPI-7711) is an EGFR inhibitor with antitumor activity and can be used to study central nervous system diseases.</p>Fórmula:C27H30N6O3Pureza:99.26% - 99.89%Forma y color:SolidPeso molecular:486.57Epitinib succinate
CAS:<p>Epitinib succinate (HMPL-813 succinate) is an orally active and brain penetration EGFR tyrosine kinase inhibitor and can be used in studies about cancer.</p>Fórmula:C28H32N6O6Pureza:98.02% - 99.79%Forma y color:SolidPeso molecular:548.59Sunvozertinib
CAS:<p>Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2.Cost-effective and quality-assured.</p>Fórmula:C29H35ClFN7O3Pureza:98.11% - 99.63%Forma y color:SolidPeso molecular:584.08Tyrphostin A25
CAS:<p>Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.</p>Fórmula:C10H6N2O3Pureza:98.76%Forma y color:Yellow Green Powder /Off-White SolidPeso molecular:202.17PD 174265
CAS:<p>PD 174265 is an effective, selective and reversible inhibitor of epidermal growth factor receptor (EGFR) with an IC50 of 0.45 nM.</p>Fórmula:C17H15BrN4OPureza:99.51%Forma y color:SolidPeso molecular:371.23EGFR-IN-99
CAS:<p>EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor for the study of non-small cell lung cancer (NSCLC).</p>Fórmula:C25H22FN7O3Pureza:97.75%Forma y color:SolidPeso molecular:487.49Larotinib
CAS:<p>Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.</p>Fórmula:C24H26ClFN4O4Pureza:98.45%Forma y color:SolidPeso molecular:488.94SKLB 1028
CAS:<p>SKLB 1028, an oral EGFR/FLT3/Abl inhibitor, excels in AML and CML with Abl mutations.</p>Fórmula:C24H29N9Pureza:99.90% - >99.99%Forma y color:SolidPeso molecular:443.55PKI-166
CAS:<p>PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.</p>Fórmula:C20H18N4OPureza:99.2%Forma y color:SolidPeso molecular:330.38CGP77675
CAS:<p>CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and</p>Fórmula:C26H29N5O2Pureza:99.66%Forma y color:SolidPeso molecular:443.54LY 456236 hydrochloride
CAS:<p>LY 456236 hydrochloride (MPMQ hydrochloride) is an mGlu1 receptor antagonist with an ic50 value of 143 nM.</p>Fórmula:C16H16ClN3O2Pureza:99.95%Forma y color:SolidPeso molecular:317.77HKI-357
CAS:<p>HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.</p>Fórmula:C31H29ClFN5O3Pureza:99.91%Forma y color:SolidPeso molecular:574.05EGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Fórmula:C36H46BrN8O2PForma y color:SolidPeso molecular:733.68EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Fórmula:C28H33BrN7O2PForma y color:SolidPeso molecular:610.49Labuxtinib
CAS:<p>Labutinib is a selective inhibitor of the c-kit tyrosine kinase [1].</p>Fórmula:C20H16FN5O2Pureza:99.77%Forma y color:SolidPeso molecular:377.37EGFR-IN-85
CAS:<p>EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR</p>Fórmula:C26H30N8O2Pureza:98%Forma y color:SolidPeso molecular:486.57BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Fórmula:C16H12BrN5Forma y color:SolidPeso molecular:354.2PF-06459988
CAS:<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Fórmula:C19H22ClN7O3Pureza:98%Forma y color:SolidPeso molecular:431.88(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Fórmula:C16H14N2O2Forma y color:SolidPeso molecular:266.29EGFR-IN-61
CAS:<p>EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).</p>Fórmula:C33H37ClN8O3Pureza:98%Forma y color:SolidPeso molecular:629.15JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Fórmula:C22H23BrFN5O2Pureza:98%Forma y color:SolidPeso molecular:488.35BEBT-109
CAS:<p>BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.</p>Fórmula:C27H32N8O3Pureza:97.26%Forma y color:SolidPeso molecular:516.6DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Fórmula:C28H27F2N7O3Pureza:98%Forma y color:SolidPeso molecular:547.562′-Thioadenosine
CAS:<p>2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against</p>Fórmula:C10H13N5O3SPureza:98%Forma y color:SolidPeso molecular:283.31Lifirafenib
CAS:<p>Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant</p>Fórmula:C25H17F3N4O3Pureza:98% - 98.25%Forma y color:SolidPeso molecular:478.42EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Fórmula:C16H9ClIN3Forma y color:SolidPeso molecular:405.62HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Fórmula:C27H33N7O3Forma y color:SolidPeso molecular:503.6EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Fórmula:C31H34N6O3Forma y color:SolidPeso molecular:538.64BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Fórmula:C22H25BrN4O2Pureza:99.02%Forma y color:SolidPeso molecular:457.36EGFR/CSC-IN-1
CAS:<p>EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potential</p>Fórmula:C54H54Cl2FN7O7S2Pureza:98%Forma y color:SolidPeso molecular:1067.08JND3229
CAS:<p>JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.</p>Fórmula:C33H41ClN8O2Pureza:98.75%Forma y color:SolidPeso molecular:617.18EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Fórmula:C26H25ClN6O2Forma y color:SolidPeso molecular:488.97BMS-599626 Hydrochloride
CAS:<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Fórmula:C27H28ClFN8O3Pureza:99.98%Forma y color:SolidPeso molecular:567.01PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Fórmula:C23H18ClF2N3O2SPureza:98.84%Forma y color:SolidPeso molecular:473.92EGFR mutant-IN-1
<p>EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.</p>Fórmula:C34H39ClFN7O2Pureza:98%Forma y color:SolidPeso molecular:632.17EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Fórmula:C32H28BrF3N6O4SForma y color:SolidPeso molecular:729.57MS 154
CAS:<p>MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.</p>Fórmula:C46H54ClFN8O8Forma y color:SolidPeso molecular:901.42EGFR-IN-33
CAS:<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Fórmula:C26H25ClN6O2Forma y color:SolidPeso molecular:488.97Nazartinib S-enantiomer
CAS:<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Fórmula:C26H31ClN6O2Pureza:98%Forma y color:SolidPeso molecular:495.02EGFR-IN-1
CAS:<p>EGFR-IN-1: an oral, irreversible EGFR inhibitor targeting L858R/T790M mutations with high selectivity, showing potent antitumor effects.</p>Fórmula:C28H30N6O4Pureza:98%Forma y color:SolidPeso molecular:514.58Simotinib
CAS:<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Fórmula:C25H26ClFN4O4Pureza:99.7%Forma y color:SolidPeso molecular:500.95Sevabertinib
CAS:<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Fórmula:C24H25ClN4O5Pureza:99.81%Forma y color:SolidPeso molecular:484.93EGFR-IN-1 hydrochloride
CAS:<p>EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.</p>Fórmula:C28H31ClN6O4Pureza:99.16%Forma y color:SolidPeso molecular:551.04EGFR-IN-87
CAS:<p>EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,</p>Fórmula:C28H33N7O2Pureza:98.64%Forma y color:SolidPeso molecular:499.61BGB-8035
CAS:<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Fórmula:C24H31N5O4Pureza:96.74%Forma y color:SolidPeso molecular:453.53EGFR/ErbB-2 inhibitor-1
CAS:<p>EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.</p>Fórmula:C23H15ClFN3OS2Pureza:98.93%Forma y color:SolidPeso molecular:467.97EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Fórmula:C32H23ClF3N7O4Pureza:99.51%Forma y color:SolidPeso molecular:662.02BML-265
CAS:<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Fórmula:C18H15N3O2Forma y color:SolidPeso molecular:305.331EGFR-IN-35
CAS:<p>EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.</p>Fórmula:C25H24ClN7O2Forma y color:SolidPeso molecular:489.96EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Fórmula:C16H16N4O2SForma y color:SolidPeso molecular:328.39EG31
CAS:<p>EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.</p>Fórmula:C30H13Br2N3O6Forma y color:SolidPeso molecular:671.25JBJ-09-063
CAS:<p>JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.</p>Fórmula:C31H29FN4O3SForma y color:SolidPeso molecular:556.65HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Fórmula:C19H14BrF3N2OForma y color:SolidPeso molecular:423.23JBJ-02-112-05
CAS:<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Fórmula:C27H20N4O2SPureza:98%Forma y color:SolidPeso molecular:464.54EGFR-IN-135
<p>EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.</p>Fórmula:C12H14N4OS2Forma y color:SolidPeso molecular:294.4HER2-IN-8
CAS:<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Fórmula:C26H25F2N9O3Forma y color:SolidPeso molecular:549.53EGFR/HER2-IN-7
<p>EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.</p>Fórmula:C19H21N3O2SForma y color:SolidPeso molecular:355.45EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Forma y color:SolidSacibertinib
CAS:<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Fórmula:C32H31ClN6O4Forma y color:SolidPeso molecular:599.08EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Fórmula:C27H31ClN7O3PForma y color:SolidPeso molecular:568.01EGFR-IN-38
CAS:<p>EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.</p>Fórmula:C25H24ClN7O2Forma y color:SolidPeso molecular:489.96EGFR-IN-126
CAS:<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Fórmula:C28H28BrFN4O3Forma y color:SolidPeso molecular:567.45EGFR-IN-149
CAS:<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Fórmula:C16H15N3OSForma y color:SolidPeso molecular:297.375EGFR-IN-160
CAS:<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Fórmula:C15H12N2O4Forma y color:SolidPeso molecular:284.27EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Fórmula:C14H11BrN4O2SForma y color:SolidPeso molecular:379.23EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Fórmula:C33H28N6O3SForma y color:SolidPeso molecular:588.68EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Fórmula:C21H23N3O5Forma y color:SolidPeso molecular:397.424EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Fórmula:C26H28ClN3O4Forma y color:SolidPeso molecular:481.97Andamertinib
CAS:<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Fórmula:C31H36N8O3Forma y color:SolidPeso molecular:568.669EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Fórmula:C30H26N8OForma y color:SolidPeso molecular:514.58EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Fórmula:C31H30FN7OForma y color:SolidPeso molecular:535.61HER2-IN-7
CAS:<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Fórmula:C28H26F3N7O3Forma y color:SolidPeso molecular:565.55Tarloxotinib bromide
CAS:<p>Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.</p>Fórmula:C24H24Br2ClN9O3Pureza:99.52%Forma y color:SolidPeso molecular:681.77Neptinib
CAS:<p>Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.</p>Fórmula:C22H23ClFN5O2Forma y color:SolidPeso molecular:443.90HER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Fórmula:C20H18N4O3SForma y color:SolidPeso molecular:394.447NSC381467
CAS:<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C20H16O7Forma y color:SolidPeso molecular:368.34EGFR-IN-23
CAS:<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Fórmula:C36H44BrN10O3PForma y color:SolidPeso molecular:775.68EGFR/HER2-IN-4
<p>EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.</p>Forma y color:SolidEGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Forma y color:SolidBPI-15086
CAS:<p>BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.</p>Fórmula:C29H33ClN8O4Forma y color:SolidPeso molecular:593.08ES-072
CAS:<p>ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.</p>Fórmula:C25H27F3N8O2Forma y color:SolidPeso molecular:528.53SST0116CL1
CAS:<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Fórmula:C22H31ClN4O6Forma y color:SolidPeso molecular:482.96EGFR-IN-139
CAS:<p>EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).</p>Fórmula:C27H25ClN2O4Forma y color:SolidPeso molecular:476.951HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Fórmula:C26H32N8O3Forma y color:SolidPeso molecular:504.58HER2-IN-12
<p>HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.</p>Fórmula:C17H18BrN5O2SForma y color:SolidPeso molecular:436.33LSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Fórmula:C21H20ClN3O4Forma y color:SolidPeso molecular:413.854EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Fórmula:C30H35FN6O3Forma y color:SolidPeso molecular:546.64EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Fórmula:C24H15FO3Forma y color:SolidPeso molecular:370.37EGFR-IN-147
CAS:<p>EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.</p>Fórmula:C13H13N5OForma y color:SolidPeso molecular:255.275Tesevatinib tosylate
CAS:<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Fórmula:C31H33Cl2FN4O5SForma y color:SolidPeso molecular:663.59EGFR-IN-132
CAS:<p>EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.</p>Fórmula:C27H31N7O3Forma y color:SolidPeso molecular:501.58Tyrphostin 63
CAS:<p>Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.</p>Fórmula:C10H8N2OForma y color:SolidPeso molecular:172.183EGFR-IN-133
CAS:<p>EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.</p>Fórmula:C27H29F2N7O3Forma y color:SolidPeso molecular:537.56EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Fórmula:C26H27ClN6O2Forma y color:SolidPeso molecular:490.98Pred17
<p>Pred17 is an effective EGFR inhibitor with potential applications in lung cancer research.</p>Fórmula:C27H22BN3OForma y color:SolidPeso molecular:415.29NS-062
CAS:<p>NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.</p>Fórmula:C28H30Cl2F2N6O4Forma y color:SolidPeso molecular:623.48D-69491 hydrochloride
CAS:<p>D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.</p>Fórmula:C25H26Cl2FN7O3Forma y color:SolidPeso molecular:562.42EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Fórmula:C27H25N3O6SForma y color:SolidPeso molecular:519.57EGFR-IN-7
CAS:<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Fórmula:C32H41BrN9O2PPureza:95.32% - 99.64%Forma y color:SolidPeso molecular:694.6Nimotuzumab (powder)
CAS:<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Forma y color:LiquidHMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Forma y color:Odour LiquidTLC9995-0188
CAS:<p>Tyrosine-protein kinase ABL, IC50: 1500 nM</p>Fórmula:C16H15N5Forma y color:Yellow SolidPeso molecular:277.331Duligotuzumab
CAS:<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Pureza:95%Forma y color:LiquidRef: TM-T80604
Producto descatalogadoEGFR-IN-82
CAS:<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Fórmula:C32H41BrN9O2PPureza:98%Forma y color:SolidPeso molecular:694.6Ref: TM-T78788
Producto descatalogadoYK-029A
CAS:<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Fórmula:C27H32N8O2Pureza:98%Forma y color:SolidPeso molecular:500.6Ref: TM-T79461
Producto descatalogadoEGFR-IN-122
CAS:<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Fórmula:C19H20N4O3Forma y color:SolidPeso molecular:352.39Ref: TM-T200157
Producto descatalogadoEGFR-IN-123
CAS:<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Fórmula:C24H27F3N6OForma y color:SolidPeso molecular:472.51Ref: TM-T200485
Producto descatalogado
